On June 22, WuXi AppTec rose 3.34% in regular trading, trading at HK$133.0/share, with turnover of HK$476 million.

On the news front, the company recently completed the repurchase of approximately 20.15 million H-shares under its H-Share Award Trust Scheme, totaling HK$2.5 billion and representing roughly 0.68% of total share capital. Additionally, the company disclosed a nearly RMB 1 billion A-share buyback plan on June 9 and has been repurchasing approximately RMB 100 million worth of A-shares daily since June 12, with shares designated for employee stock ownership plans.

Meanwhile, the broader innovative drug sector has been gaining momentum, with multiple pharmaceutical companies launching buyback and stake-increase programs in June, gradually restoring market confidence in the industry. Sector peers including WuXi Biologics and GenScript Biotech also recorded gains during recent sessions, reflecting a broader recovery in the contract research and manufacturing organization space.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)